Personalized and Dynamic Therapy for Breast Cancer: A Preclinical Perspective

Abstract

Breast cancer is one of the leading causes of mortality worldwide. Genomic studies have provided key insights into how breast cancer develop, evolve, metastasize, recurrence and respond to treatment. The advance of next-generation sequencing (NGS) and bioinformatics has led to an unprecedented view of the breast cancer genome and its evolution, and made the dynamic monitoring of recurrence and selective evolution of breast cancer during therapy a reality. Here we illustrate a proposed preclinical strategy of personalized and dynamic therapy for breast cancer based on the technologies of NGS and patient-derived tumor xenograft (PDX) model. The goal of this strategy is to provide a preclinical model of personalized and dynamic therapy for breast cancer to improve patients' outcomes.

Bioinformatics and personalized medicine in the U.S.: A comprehensive review: Scrutinizing the advancements in genomics and their potential to revolutionize healthcare delivery

“…In the context of cancer, for instance, NGS and bioinformatics have provided an unprecedented view of the cancer genome and its evolution. Lan et al (2017) illustrate this through the lens of breast cancer, where genomic studies have shed light on the disease's development, metastasis, recurrence, and response to treatment. The integration of NGS with patient-derived tumor xenograft (PDX) models proposes a personalized and dynamic therapy strategy, aiming to improve patient outcomes by tailoring treatments based on individual genomic profiles.…”